eJHaem (Jun 2024)
Richter transformation acquiring PLCG2 mutation during Bruton tyrosine kinase inhibitors treatment
- Takafumi Tsushima,
- Nobue Sato,
- Yong‐Mei Guo,
- Hirotaka Nakamura,
- Kodai Kunisada,
- Song‐Gi Chi,
- Kenta Akie,
- Yuki Takahashi,
- Saki Nakamura,
- Kaoru Shimada,
- Genichiro Ishii,
- Yosuke Minami,
- Junichiro Yuda
Affiliations
- Takafumi Tsushima
- Department of Hematology and Oncology National Cancer Center Hospital East Kashiwa Japan
- Nobue Sato
- Pharmaceutical Department National Cancer Center Hospital East Kashiwa Japan
- Yong‐Mei Guo
- Department of Hematology and Oncology National Cancer Center Hospital East Kashiwa Japan
- Hirotaka Nakamura
- Department of Hematology and Oncology National Cancer Center Hospital East Kashiwa Japan
- Kodai Kunisada
- Department of Hematology and Oncology National Cancer Center Hospital East Kashiwa Japan
- Song‐Gi Chi
- Department of Hematology and Oncology National Cancer Center Hospital East Kashiwa Japan
- Kenta Akie
- Department of Clinical Laboratories National Cancer Center Hospital East Kashiwa Japan
- Yuki Takahashi
- Department of Clinical Laboratories National Cancer Center Hospital East Kashiwa Japan
- Saki Nakamura
- Department of Clinical Laboratories National Cancer Center Hospital East Kashiwa Japan
- Kaoru Shimada
- Department of Radiology National Cancer Center Hospital East Kashiwa Japan
- Genichiro Ishii
- Department of Pathology National Cancer Center Hospital East Kashiwa Japan
- Yosuke Minami
- Department of Hematology and Oncology National Cancer Center Hospital East Kashiwa Japan
- Junichiro Yuda
- Department of Hematology and Oncology National Cancer Center Hospital East Kashiwa Japan
- DOI
- https://doi.org/10.1002/jha2.891
- Journal volume & issue
-
Vol. 5,
no. 3
pp. 642 – 645
Abstract
No abstracts available.
